NASDAQ$BTAI
Bioxcel Therapeutics Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Reported third quarter results and provided a business update.
BioXcel Therapeutics reported a net loss of $24.8 million for the third quarter of 2020. The company's NDA submission for BXCL501 is on track for Q1 2021, and clinical trials for BXCL501 and BXCL701 are progressing. The company's cash position remains strong at $233.4 million.
- Completed pre-NDA meeting with the FDA and initiated rolling submission of the NDA for BXCL501.
- TRANQUILITY and RELEASE studies are on track; preparing to initiate a Phase 2 trial with BXCL501 in patients with agitation associated with delirium.
- Presented encouraging data from the two ongoing combination trials of BXCL701 and KEYTRUDA® at SITC.
- Cash and cash equivalents totaled approximately $233.4 million as of September 30, 2020.
Headline financials
Revenue & EPS history
Bioxcel Therapeutics · Revenue · Quarterly
$20K
Revenue by segment
Bioxcel Therapeutics · $206K total across 1 segment · Q1 2026
- IGALMI$206K—100.0%
Forward guidance
The company is focused on advancing its BXCL501 and BXCL701 programs and expects to achieve key milestones well into 2022.
Tailwinds
- Complete NDA submission for BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorders on track for Q1 2021.
- TRANQUILITY and RELEASE studies are on track.
- Preparing to initiate a Phase 2 trial with BXCL501 in patients with agitation associated with delirium.
- Encouraging data from the two ongoing combination trials of BXCL701 and KEYTRUDA® was presented at SITC.
- Strong cash position of $233 million to fund key milestones well into 2022.
Headwinds
- Limited operating history.
- Incurrence of significant losses.
- Need for substantial additional funding and ability to raise capital when needed.
- Limited experience in drug discovery and drug development.
- Dependence on the success and commercialization of BXCL501 and BXCL701 and other product candidates.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2020
-3.1%
Avg return
Earnings day
-5.6%
Avg return
5 days after
-10.0%
Avg return
30 days after
30%
10 / 33 earnings
Positive
+38.7%
Q3 2022
Best reaction
-44.1%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.8% | -9.9% | — | |
| Q4 2025 | -5.6% | -10.9% | -22.6% | |
| Q3 2025 | -16.0% | -9.4% | -0.5% | |
| Q2 2025 | +6.5% | -14.4% | -47.0% | |
| Q1 2025 | +0.0% | -4.8% | +6.8% | |
| Q4 2024 | +6.0% | -11.9% | -14.2% | |
| Q3 2024 | -8.2% | -2.6% | -33.4% | |
| Q2 2024 | -1.0% | -20.5% | -35.9% | |
| Q1 2024 | -1.4% | +0.5% | -33.3% | |
| Q4 2023 | -1.0% | -7.6% | -3.8% | |
| Q3 2023 | -20.1% | -25.0% | -41.2% | |
| Q2 2023 | -44.1% | -41.5% | -54.3% | |
| Q1 2023 | +17.7% | +18.6% | -9.6% | |
| Q4 2022 | -27.2% | -28.3% | -39.1% | |
| Q3 2022 | +38.7% | +41.1% | +49.2% | |
| Q2 2022 | -9.7% | -5.9% | -9.4% | |
| Q1 2022 | -10.6% | -6.5% | -6.7% | |
| Q4 2021 | -8.3% | -20.3% | -9.4% | |
| Q3 2021 | -2.4% | -19.7% | -35.5% | |
| Q2 2021 | +2.2% | -1.6% | +19.3% | |
| Q1 2021 | +8.1% | +3.1% | +27.2% | |
| Q4 2020 | +3.8% | +2.0% | -20.7% | |
| Q3 2020 | -4.1% | -8.6% | -23.8% | |
| Q2 2020 | -4.7% | -6.3% | +0.5% | |
| Q1 2020 | +0.1% | +9.6% | +6.7% | |
| Q4 2019 | -3.9% | -39.8% | -35.5% | |
| Q3 2019 | +12.4% | +40.6% | +48.3% | |
| Q2 2019 | -15.1% | -7.5% | +2.6% | |
| Q1 2019 | +12.8% | +9.4% | +5.3% | |
| Q4 2018 | -6.6% | +12.3% | +23.1% | |
| Q3 2018 | -7.9% | -12.6% | -21.8% | |
| Q2 2018 | -1.8% | -9.6% | -8.5% | |
| Q1 2018 | -4.9% | +3.6% | -1.9% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro